Hormonal
Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.
If GLP-1 mono-agonists (like semaglutide) are not enough, dual agonists (like cotadutide or pemvidutide) may offer greater liver fat reduction and fibrosis improvement. However, these drugs are more complex and may cause more side effects. They are currently in clinical trials and not yet standard care. Discuss with your hepatologist if you are a candidate for these newer agents, especially if you have significant liver fat but stable diabetes.
Boland et al. explored the effects of cotadutide vs. liraglutide which was dosed to achieve similar weight loss. Their data demonstrated a greater reduction in liver triglycerides, diacylglycerol and cholesterol esters with the dual agonist vs. the GLP-1 mono-agonist liraglutide.
Why this rating
Evidence is largely from preclinical mouse models and early-phase human trials; long-term histological data is still emerging.
Source
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Philip N. Newsome et al. · Journal of Hepatology · 2023
DOI 10.1016/j.jhep.2023.07.033
More from this paper
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide) resolve MASH histology primarily through substantial weight loss and improved insulin resistance, rather than direct hepatocyte effects.Good
- The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →